Fiche publication
Date publication
décembre 2024
Journal
Bulletin du cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr POCHON Cécile
Tous les auteurs :
Roussel A, Léglise C, Rialland F, Duplan M, Falaque F, Boulanger C, Cardine AM, Alimi A, Pochon C, Rabian F, Hautefeuille C, Corbel A, Dupraz C, Lervat C, Alby-Laurent F
Lien Pubmed
Résumé
Children and adolescents who are being treated or have been treated for acute leukemia have a secondary immunodeficiency linked to chemotherapy, resulting in an increased risk of infections. Some of which can be prevented by vaccination but its effectiveness is not optimal during chemotherapy. Upon cessation of chemotherapy, the time required for immune reconstitution varies from three months to more than a year, depending on lymphocyte subpopulations, the patient's age, and the intensity of the treatment received. Although they may have regained their immune functions, studies show that most patients have lost part of their vaccine-induced protection post-chemotherapy and require booster doses of vaccines. Most practitioners agree on the importance of vaccinating or revaccinating these children, but practices are heterogeneous among pediatric hematologist-oncologists in France. Based on a practice study and a recent review of the literature, this work aims to propose new French recommendations for the vaccination strategy to be adopted for children and adolescents treated or recently treated for acute leukemia, excluding allogeneic transplant recipients, in 2024. These recommendations specifically include the vaccination protocols for human papillomavirus and meningococcal infections but do not address the COVID-19 vaccination, as its guidelines are subject to rapid changes.
Mots clés
Acute leukemia, Chemotherapy, Children, Chimiothérapie, Enfant, Immunocompromised host, Immunodéprimé, Leucémie aiguë, Practice guidelines, Recommandations, Vaccination
Référence
Bull Cancer. 2024 12 19;:
